Biological causes and brain compensation of swallowing problems in Parkinson's disease

Biological Determinants and Neural Compensatory Mechanisms of Oropharyngeal Dysphagia in Parkinson's Disease

Observational Heinrich-Heine University, Duesseldorf · NCT07299448

This study will test whether specific biological markers and brain activity patterns explain and help compensate for swallowing problems in people with Parkinson's disease.

Quick facts

Study typeObservational
Enrollment100 (estimated)
Ages18 Years and up
SexAll
SponsorHeinrich-Heine University, Duesseldorf Academic / other
Locations1 site (Düsseldorf, North Rhine-Westphalia)
Trial IDNCT07299448 on ClinicalTrials.gov

What this trial studies

This observational study enrolls people with idiopathic Parkinson's disease across all disease stages to combine clinical swallowing exams, cough-reflex and pharyngeal sensitivity testing, functional MRI of the swallowing network, and proteomic analyses. Participants will undergo standardized clinical and instrumental swallow assessments alongside neuroimaging to identify neural compensation and correlate those findings with blood-derived biological markers. The goal is to link clinical severity and swallowing outcomes to specific neural and molecular signatures that may explain why some patients preserve safe swallowing. Results will inform biomarkers and targets for future intervention trials.

Who should consider this trial

Good fit: Ideal candidates are adults with idiopathic Parkinson's disease (any stage) who can follow study procedures, take food and fluids by mouth, and have no contraindications to MRI.

Not a fit: Patients with exclusive tube feeding, other causes of oropharyngeal dysphagia (e.g., stroke, head and neck cancer), implanted electronic devices that preclude MRI, or asthma/COPD are excluded and would not benefit from participation.

Why it matters

Potential benefit: If successful, the work could identify biomarkers and neural signatures that improve prediction of aspiration risk and guide targeted therapies to reduce pneumonia, malnutrition, and medication problems.

How similar studies have performed: Prior imaging and biomarker studies have suggested neural compensation and molecular changes in swallowing, but combining multimodal neuroimaging with proteomics in PD is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

.- Patients with idiopathic Parkinson's disease diagnosed according to the MDS diagnostic criteria

* Participation possible in all disease stages, regardless of the presence or absence of subjective or objective oropharyngeal dysphagia
* Cognitive ability sufficient to comply with the study paradigm
* Daily oral intake of food and fluids (exclusion of patients with exclusive tube feeding)

Exclusion Criteria:

* Presence of other conditions associated with oropharyngeal dysphagia, such as stroke, head and neck cancer, neuroinflammatory diseases, neuromuscular disorders, or other brain injuries
* Presence of electronic stimulation devices (e.g., pacemaker, deep brain stimulation) or other contraindications for MRI imaging
* Diagnosis of asthma or COPD (due to performance of the cough reflex test in "Block 1: Assessment of OD and pharyngeal hyposensitivity")

Where this trial is running

Düsseldorf, North Rhine-Westphalia

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Parkinsons DiseaseOropharyngeal DysphagiaDysphagia, Swallowing Disorder, Parkinson's Disease, Swallowing Compensation, Neuroimaging Biomarkers, Functional MRI, Proteomics
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.